Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BNT323 versus investigator's choice chemotherapy in recurrent HER2-expressing endometrial cancer
NL-OMON60037Phase 3Recruiting
- Sponsor
- BioNTech SE
- Start
- Feb 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of trastuzumab pamirtecan in endometrial cancer (EC), sponsored by BioNTech SE. Primary endpoint: Progression-free survival by blinded independent central review. Started Feb 2026; status: recruiting.
02
Drugs
trastuzumab pamirtecan
03
Conditions
endometrial cancer (EC)
Beyond the preview
Go deeper on NL-OMON60037.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60037.